Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Polycomb repressive complex 2 is a critical mediator of allergic inflammation
Christine R. Keenan, Nadia Iannarella, Alexandra L. Garnham, Alexandra C. Brown, Richard Y. Kim, Jay C. Horvat, Philip M. Hansbro, Stephen L. Nutt, Rhys S. Allan
Christine R. Keenan, Nadia Iannarella, Alexandra L. Garnham, Alexandra C. Brown, Richard Y. Kim, Jay C. Horvat, Philip M. Hansbro, Stephen L. Nutt, Rhys S. Allan
View: Text | PDF
Research Article Immunology Inflammation

Polycomb repressive complex 2 is a critical mediator of allergic inflammation

  • Text
  • PDF
Abstract

Strategies that intervene with the development of immune-mediated diseases are urgently needed, as current treatments mostly focus on alleviating symptoms rather than reversing the disease. Targeting enzymes involved in epigenetic modifications to chromatin represents an alternative strategy that has the potential to perturb the function of the lymphocytes that drive the immune response. Here, we report that 2 major epigenetic silencing pathways are increased after T cell activation. By specific inactivation of these molecules in the T cell compartment in vivo, we demonstrate that the polycomb repressive complex 2 (PRC2) is essential for the generation of allergic responses. Furthermore, we show that small-molecule inhibition of the PRC2 methyltransferase, enhancer of zeste homolog 2 (Ezh2), reduces allergic inflammation in mice. Therefore, by systematically surveying the pathways involved in epigenetic gene silencing we have identified Ezh2 as a target for the suppression of allergic disease.

Authors

Christine R. Keenan, Nadia Iannarella, Alexandra L. Garnham, Alexandra C. Brown, Richard Y. Kim, Jay C. Horvat, Philip M. Hansbro, Stephen L. Nutt, Rhys S. Allan

×

Figure 3

Ezh2 is required to generate antigen-specific memory.

Options: View larger image (or click on image) Download as PowerPoint
Ezh2 is required to generate antigen-specific memory.
(A) Bio-Plex analy...
(A) Bio-Plex analysis of cytokine levels in bronchoalveolar lavage (BAL) fluid following OVA challenge in Ezh2fl/fl Cd4Cre and control Ezh2fl/fl mice. Fold change over mean level in control (alum-sensitized) mice is shown as mean and SD together with individual data points. Statistical analysis by multiple unpaired t tests corrected for multiple comparisons using the Holm-Sidak method; n = 2 (Ezh2fl/fl), n = 8 (Ezh2fl/fl Cd4Cre). Only cytokines induced more than 2-fold by OVA are shown. (B) IFN-γ levels in BAL fluid following OVA challenge. The x-axis labels indicate initial sensitization. Fold change over mean of alum-sensitized control mice shown as individual data points together with mean and SD. Statistical analysis by 2-way ANOVA. Group sizes are as in A. (C) OVA-specific IgE and total IgE detected in serum of mice following OVA challenge. The x-axis labels indicate initial sensitization. Individual data points as well as mean and SD are shown; n = 3 per group except for nonimmunized C57BL/6 (Bl/6), where n = 1 is shown for reference. Statistical analysis by Kruskal-Wallis H test with Dunn’s post hoc test. (D) Intracellular cytokine staining of splenic antigen-experienced (CD44+) CD4+ T cells 3 days after OVA sensitization protocol (10 days after initial sensitization). Cells were stimulated with PMA/ionomycin for 5 hours in the presence of GolgiStop protein transport inhibitor for the final 2 hours. (E) Quantification of the results in D. Individual data points together with mean and SEM are shown. Statistical analysis by Mann-Whitney U test (n = 6 per group). (F) OVA class II tetramer staining of cells pooled from mechanically homogenized spleen and peripheral lymph nodes after OVA sensitization protocol as in D. (G) Quantification of results in F. Mean and SEM together with individual data points are shown for n = 3 (Bl/6), n = 6 (Ezh2fl/fl), n = 5 (Ezh2fl/fl Cd4Cre). Statistical analysis by Kruskal-Wallis H test with Dunn’s post hoc test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts